GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies

This early-phase study tests GIC-102, a type of treatment using natural killer (NK) cells from a healthy donor, given intravenously to patients with advanced solid cancers (like lung, breast, or colon cancer) or blood cancers (like non-Hodgkin lymphoma or multiple myeloma) that have not responded to prior treatments. NK cells are immune cells that naturally attack cancer. **You may be eligible if...** - You are 19 or older with advanced solid cancer, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma - You have at least one measurable or evaluable tumor - Your general health is good (ECOG 0–1) with a life expectancy of at least 12 weeks - Your blood, kidney, and liver function are acceptable **You may NOT be eligible if...** - You have significant heart disease or active hepatitis B, C, or HIV - You have had a prior organ transplant or allogeneic cell therapy within 6 months - You are on immunosuppressants or have an immunodeficiency - You had major surgery within 4 weeks or minor surgery within 2 weeks - You are pregnant or breastfeeding - You have a known allergy to the study drug or the chemotherapy prep medications Talk to your doctor to see if this trial is right for you.